Biohaven's BHV-1420 reduces disease-driving antibodies by over 90% in mouse study
BHVN•Biohaven presented preclinical results for BHV-1420 in membranous nephropathy at ASN Kidney Week on Oct. 24, 2026. A single injection rapidly reduced circulating disease-driving antibodies by over 90% in mice.
1. Preclinical findings
Laboratory testing showed that BHV-1420 recognized most patient autoantibodies. A single injection rapidly reduced circulating disease-driving antibodies by over 90% in mice.
2. Kidney disease program
The investigational drug targets harmful autoantibodies for liver degradation without broad immunosuppression. BHV-1420 is the second program in Biohaven's TRAP kidney disease portfolio, built on technology exclusively licensed from Yale University.
